Including these compounds and their use in treatment In particular, it involves the use of BTK inhibitors in the treatment of disorders in Btk. 1. Claim 1: compound (1) in the formula,Or a pharmaceutically acceptable salt, wherein:...A3 and a83088 are independent of C, CH, CR1 or n. The E-G double ring system is selected from the group consisting of residues in the preparation group (2),where R¹¹ is independently selected from the group consisting of: a) deuterium, b) H, c) halogen, d) cyano, e) C²H₃,f) -COOH, g) -CO₂-C₁₋₆ alkyl,h) -CO-C₁₋₆ alkyl,i) -CONH-alcoxi Cj) -CONH-C₁₋₆ alkyl,k) -CON-dialquilo Cₗ₎ ₐₗqᵘⁱₗₒ C₁₋₆q Cn) alcoxi C(o) Arilo, P) heterosexual c832131；q) alquenilo Cr) C₂₋₆ alkynyl,(s) Isocyclopentanediol c83248331；R1 can be optionally replaced by one or more selected groups: halogen, hydrocarbyl c83338326；C₁₋₅ alkoxy,hidroxilo u oxo R est independientemente seleccionado del grupo que consiste en H alquilo C alquil C -NHC (O)1. C833218331-oc (o) and c833212331-c (o)；R¹³ is independently selected from the group consisting of: H and C₁₋₄ alkoxy；K aromatic ring: B1 is n or C (r8311)；B es N o C (R)B es N o C (R)b. N or C 8308es (r83044)；R831111es h, halogen, oh, tar c83218331；C₁₋₆ alkoxy,C₃₋₆ cycloalkoxy,3. Calcium isoacrylate c8321c83318325；C₁₋₃ or CN haloalkyl； wherein R⁷ may be optionally substituted with one, two or three halogens, OH, C₂₋₄ alkynyl,-C (O) NH-C (O) OH or -C (O) C₁₋₄ alkyl；R⁸ is H, halogen, OH, C₁₋₃ alkyl,C₁₋₆ alkoxy,C₃₋₆ cycloalkoxy,3. Calcium isoacrylate c8321c83318325；C₁₋₃ or CN haloalkyl； wherein R⁸ may be optionally substituted with one, two or three halogens, OH, C₂₋₄ alkynyl,-C (O) NH-C (O) OH or -C (O) C₁₋₄ alkyl；R⁹ is H, halogen, OH, C₁₋₃ alkyl,C₁₋₆ alkoxy,C₃₋₆ cycloalkoxy,3. Calcium isoacrylate c8321c83318325；C₁₋₃ or CN haloalkyl； wherein R⁹ may be optionally substituted with one, two or three halogens, OH, C₂₋₄ alkynyl,-C (O) NH-C (O) OH or -C (O) C₁₋₄ alkyl；R8304es h, halogen, oh, tar c83218331；C₁₋₆ alkoxy,C₃₋₆ cycloalkoxy,3. C
